Here are the 10-K annual reports from Zymeworks Inc. (ZYME) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow ZYME and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ZYME filings page.
Zymeworks Inc. is a biotechnology company focused on royalty-driven asset aggregation and development of multifunctional biologics for cancer, inflammation, and autoimmune disease. Its strategy combines royalty growth, selective acquisitions, internal R&D and potential stock repurchases, supported by milestone and royalty streams from major partners.
Lead asset Ziihera (zanidatamab-hrii), a HER2-targeted bispecific antibody, has approvals for HER2-positive biliary tract cancer in the United States, China, Europe and Canada, with Jazz and BeOne holding territorial rights. Zymeworks has already received $53.0 million tied to BTC approval and is entitled to up to $440.0 million in near-term GEA approval milestones across the U.S., EU, Japan and China, plus $89.0 million for a third indication and tiered royalties up to 20% on substantial global sales tiers.
To monetize part of this stream, a subsidiary sold 30% of future Ziihera royalties under certain Jazz and BeOne agreements and borrowed $250.0 million from Royalty Pharma, with total repayment capped at approximately $481.3 million by December 31, 2042, or $412.5 million if repaid by December 31, 2033. Zymeworks retains 70% of Ziihera royalties and all milestones.
The company also highlights pasritamig, a KLK2-targeting T cell engager from a Johnson & Johnson collaboration now in multiple Phase 3 trials in castration-resistant prostate cancer, and an expanding wholly owned pipeline of ADCs (ZW191, ZW251, ZW220) and multispecific antibodies (ZW209, ZW1528) built on proprietary Azymetric, TOPO1i, EFECT and ProTECT platforms. As of February 26, 2026, Zymeworks had 73,749,607 common shares outstanding, and reported a non‑affiliate market value of approximately $649.5 million based on its most recent second fiscal quarter.